1. Exploring the effects of nutrient deprivation and waste accumulation on T cells and oncolytic adenoviruses in order to create immune activators for tumour therapy
- Author
-
Frost, Sally Claire, D'Angiolella, Vincenzo, and Seymour, Leonard
- Subjects
Cancer--Immunotherapy ,Virology ,Oncolytic virotherapy ,Oncology - Abstract
High metabolic stress is a hallmark of cancer. Tumours are characterised by a depletion of amino acids and accumulation of lactic acid, both promote an immunosuppressive milieu and may limit success of cancer immunotherapy. One such therapeutic approach is represented by an oncolytic adenovirus, EnAdenotucirev (EnAd), engineered to express a bispecific T cell engager (BiTE) targeting EpCAM. This platform offers a multi-pronged strategy to directly lyse cancer cells and elicit T cell-mediated cytotoxicity, demonstrating anti-cancer activity in ex vivo tumour models. However, the impact of nutrient depletion and lactic acid upon EnAd and the EpCAM BiTE are yet to be explored. Here, we show that the EpCAM BiTE is able to overcome nutrient depletion, likely due to its ability to hyper-activate T cells. By contrast, EnAd replication and cytolytic activity is severely impacted. This was demonstrated using artificial amino acid-depleted media and malignant ascites fluids. The opposite held true for therapeutic activity in accumulated lactic acid; BiTE functionality was severely limited due to acidification, while EnAd was less susceptible and retained its ability to replicate. The use of different BiTE formats did not relieve the inhibition observed. This work is the first to describe the impact of low pH on the activity of BiTEs, and serves to highlight the importance of utilising clinically-relevant models during the pre-clinical development of immunotherapies. Acidosis represents a hurdle for T cell-activating therapies. We propose that using EnAd to express shRNAs targeting lactic acid production in tumour cells, may reverse pH-induced immune suppression. We targeted LDHA and MCT-4, two components required to extrude lactic acid. We showed that knockdown of LDHA following infection was possible and that the shRNA-encoded EnAd retained its oncolytic and replicative capabilities. Arming oncolytic viruses with anti-acidity agents, alongside those with T cell-activating abilities, may offer a novel approach to overcome metabolic barriers of the tumour microenvironment and combat immune evasion.
- Published
- 2020